Funding Opportunity PAR-17-458 from the NIH Guide for Grants and Contracts. The Population Assessment of Tobacco and Health (PATH) Study provides the scientific community with biospecimens (urine, plasma, and serum) and related research data on behaviors, attitudes, biomarkers and health outcomes associated with tobacco use in the U.S. This opportunity allows investigators to apply for access to the biospecimens from the PATH Study. Information about the PATH Study and this resource may be found on the PATH Study series page at the University of Michigans National Addiction and HIV Data Archive Program (NAHDAP) website, part of the Inter-University Consortium for Political and Social Researchs (ICPSR) website (https://doi.org/10.3886/Series606).

The Mitsiades Lab has positions available for motivated postdoctoral research fellows in the integrative analysis of genomic, epigenomic, transcriptomic, metabolomics and proteomic large scale datasets

Funding Opportunity RFA-DK-17-509 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement is for a limited competition for clinical centers for the continuation of the Drug-induced Liver Injury Network (DILIN). The DILIN Clinical Centers are the components of the Network to identify, enroll and clinically characterize patients eligible for the DILIN. The companion RFA (RFA-DK-17-510) seeks to continue the Data Coordinating Center for DILIN Drug-induced liver injury (DILI) is one of the more challenging forms of liver disease; both in diagnosis and management. Several hundred drugs, nutritional supplements and herbal medications have been implicated in causing liver injury. Their clinical presentation can be highly variable and mimic almost any form of liver disease. Over the last 14 years, the DILIN Network throughout its publications (http://www.dilin.org/publications/) have become the major source of information and progress in understanding and possibly decreasing the burden of drug-induced liver injury for clinicians, hepatologists, researchers, and the public at large in the US and Worldwide.

Funding Opportunity RFA-DK-17-510 from the NIH Guide for Grants and Contracts. The purpose of this Funding Opportunity Announcement is for a limited competition for the continuation of the Data Coordinating Center of the Drug-induced Liver Injury Network (DILIN). The Data Coordinating Center will provide managerial, logistic, and analytic functions for the DILIN and built a collaboration with the National Center for Natural Products Research (NCNPR), University of Mississippi to attempt the identification of specific hepatotoxic ingredients in HDS implicated in liver toxicity. This RFA and companion RFA-DK-17-509 will seek the continuation of the Data Coordinating Center and six Clinical Centers

Notice NOT-HG-17-015 from the NIH Guide for Grants and Contracts

Notice NOT-HL-17-534 from the NIH Guide for Grants and Contracts

Notice NOT-NS-18-003 from the NIH Guide for Grants and Contracts

Notice NOT-OD-17-099 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-17-456 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) supports the optimization of potential therapeutic Biotechnology Products and Biologics (e.g., peptides, proteins, oligonucleotides, gene and cell therapies) for disorders identified under the NINDS mission. This track supports the further characterization and optimization of therapeutic lead(s) that showed promise as a potential therapeutic agent as evidenced by convincing animal proof-of-concept studies. Therefore, at the end of this funding period, successful projects will have delivered and optimized therapeutic candidate with demonstrated bioactivity, stability, manufacturability, bioavailability, in vivo efficacy and should be eligible for entry into the CREATE Bio Development track. The CREATE Bio Development track is a later stage program focused on the development of optimized therapeutic candidates through Investigational New Drug (IND)-enabling studies and submission of an IND package to the Food and Drug Administration (FDA).

Funding Opportunity PAR-17-457 from the NIH Guide for Grants and Contracts. This Funding Opportunity Announcement (FOA) supports SBIRs in the optimization of potential therapeutic Biotechnology Products and Biologics (e.g., peptides, proteins, oligonucleotides, gene therapies, cell therapies, and novel emerging modalities) for disorders identified under the NINDS mission. This track supports the further characterization and optimization of therapeutic agent(s) that showed promise as evidenced by relevant, rigorous, convincing in vivo studies. Therefore, at the end of this funding period, successful projects will have delivered an optimized therapeutic candidate with demonstrated bioactivity, stability, manufacturability, bioavailability, in vivo efficacy and should be eligible for entry into the CREATE Bio Development track.

The successful candidate should have a strong computational background with proven track record of having applied computational solutions to solve biological...
From Pfizer Inc. - Sun, 13 Aug 2017 06:02:30 GMT - View all California jobs

Applicants should have demonstrated scientific productivity, have a strong publication record, be able to design and execute scientific experiments...
From University of Minnesota - Fri, 11 Aug 2017 23:28:35 GMT - View all Minnesota jobs

Notice NOT-MH-17-043 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-17-455 from the NIH Guide for Grants and Contracts. The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this National Institute of Allergy and infectious Diseases (NIAID) R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nations biomedical, behavioral and clinical research needs in NIAID mission areas.

Negotiable: Paramount Recruitment: An exciting new opportunity for a Principle Scientist within Computational Biology has become available. Germany

Notice NOT-HL-17-351 from the NIH Guide for Grants and Contracts

Notice NOT-ES-17-007 from the NIH Guide for Grants and Contracts

Notice NOT-MH-17-042 from the NIH Guide for Grants and Contracts

Techniques used include porewater analysis, gas sampling, DNA and RNA extraction, molecular modification of nucleic acids, sequence analysis and ion...
From University of Delaware - Thu, 10 Aug 2017 23:14:19 GMT - View all Lewes, DE jobs

Qualified applicants should submit a cover letter, CV, statement of teaching interests and contact information for three professional references....
From Penn State University - Thu, 10 Aug 2017 22:37:54 GMT - View all University Park, PA jobs